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Abstract: SPAK and OSR1 are two protein kinases that emerged as 
attractive targets in the discovery of novel antihypertensive agents 
due to their role in regulating electrolyte balance in vivo. In this work, 
we report on the identification of an allosteric pocket on their highly 
conserved C-terminal domains, which influences their kinase activity. 
Also, we show that some known WNK-signaling inhibitors bind to this 
allosteric site. Using in silico screening, we identified Rafoxanide, an 
anti-parasitic agent, as a novel allosteric inhibitor of SPAK and OSR1. 
Collectively, this work will facilitate the rational design of novel SPAK 
and OSR1 kinase inhibitors that could be useful antihypertensive 
agents.   
Cellular cation-chloride co-transporters play important roles in 
maintaining electrolyte balance, a phenomenon that is critical to 
many physiological processes such as cell volume regulation and 
neuronal excitability.[1] Among the emerging signaling pathways 
involved in the in vivo regulation of these ion co-transporters, and 
hence electrolyte balance, is the WNK-SPAK/OSR1 signaling 
pathway.[2] The first link between this signaling pathway and 
electrolyte balance was noted when mutations in the genes 
encoding the serine/threonine protein with no lysine (K) (WNK) 
kinases resulted in an inherited form of hypertension in humans 
known as Gordon’s syndrome.[3] Subsequent studies identified 
two serine/threonine protein kinases, namely the STE20/SPS1-
related proline/alanine-rich kinase (SPAK) and the oxidative-
stress-responsive kinase 1 (OSR1), as the physiological 
substrates of WNK kinases (Figure 1a).[4] These two kinases were 
found to be able to phosphorylate a series of sodium, potassium 
and chloride ion co-transporters such as the Na-K-Cl co-
transporters 1 and 2 (NKCC1 and 2), the Na-Cl co-transporter 
(NCC) and the K-Cl co-transporter (KCC) (Figure 1a).[5] Various 
WNK, SPAK and OSR1 mouse models indicated that the 
inhibition of these kinases resulted in a lowered blood pressure 
through reduced in vivo phosphorylation of ion co-transporters.[6] 
These highlighted the WNK-SPAK/OSR1 signaling pathway as a 
plausible target in the discovery of new antihypertensive agents. 
Human SPAK and OSR1 protein kinases are 68% identical in 
sequence and share a 92-amino acids highly conserved carboxy-
Figure 1. a) A brief depiction of WNK-SPAK/OSR1 signaling. b) Crystal 
structure of the human OSR1 CCT domain (452-end) showing the key primary 
and secondary pockets.  
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terminal (CCT) domain (aa. 436-527 for OSR1 and 456-547 for 
SPAK), which is 79% identical in sequence.[7] The CCT domain, 
which is highly conserved in orthologues of SPAK and OSR1 
kinases in Caenorhabditis elegans, Drosophila and Xenopus,[8] 
binds RFxV (Arg-Phe-Xaa-Val) motifs of the upstream and 
downstream protein partners.[5c, 7, 9] The crystal structure of OSR1 
CCT domain in complex with an 18-mer RFQV peptide derived 
from the upstream kinase WNK4 identified a C-terminal site, 
termed the primary pocket, as being responsible for mediating the 
binding to the upstream WNK kinases and downstream protein 
binders, i.e. ion co-transporters (Figure 1b).[8] Notably, a highly 
conserved second pocket, termed the secondary pocket, formed 
by a large loop connecting α3 to β4 was also observed (Figure 
1b),[8] but the function of this site remained elusive. Intrigued by 
this, we sought to understand whether this secondary pocket had 
an impact on the catalytic activity of SPAK and OSR1 kinases and 
whether it is amenable to targeting by small molecules. 
Initially, we explored the effect of the secondary pocket on 
catalytic activity of OSR1. To do this, we mutated the secondary 
pocket L440, S443 and V507 amino acid residues of OSR1. 
These three mutations were introduced to OSR1 T185E, where 
threonine 185 was mutated into glutamic acid to mimic WNK 
phosphorylation at this site, making the kinase constitutively 
active in vitro.[4] GST-tagged full length OSR1 T185E with single 
point mutations in the CCT domain was overexpressed and 
purified from HEK293. The catalytic activity of these kinases was 
established using Promega’s luminescence ADP-GloÔ kinase 
assay.[10] As shown in Figure 2a, out of the three mutations 
studied, L440A and V507A showed significant in vitro reduction in 
the kinase activity of OSR1 T185E. Mutation of S443 into alanine, 
however, did not affect the kinase activity. To confirm that the 
L440A and V507A secondary pocket mutations, which influenced 
the kinase activity, have no effect on OSR1’s CCT domain ability 
to bind WNK kinases, we used a fluorescence polarization assay 
for measuring the binding of OSR1 CCT domain to an 18-mer 
RFQV peptide derived from the upstream kinase WNK.[6c] As a 
reference, we employed OSR1 CCT with a single point mutation 
L473A, which is located in the primary pocket and is known to 
reduce the binding of SPAK and OSR1 to WNK kinases.[11] The 
results revealed that the mutation in the primary pocket site, 
L473A, led to a significant reduction in binding to the WNK 18-mer 
RFQV peptide in agreement with the literature (CCT domain wild 
type Kd = 2.11 μM  and CCT domain L473A Kd = 13.17 μM) 
(Figure 2b). Interestingly, the introduction of single point 
mutations in the secondary pocket did not affect the binding 
between OSR1 C-terminal domain and the WNK4 18-mer RFQV 
peptide (CCT domain L440A Kd = 1.83 μM and CCT domain 
V507V Kd = 1.75 μM) (Figure 2b). Together, this data represents 
the first evidence of the secondary pocket of OSR1 CCT domain 
being able to impact its kinase activity. Given the high similarity in 
sequence of the CCT domain of SPAK and OSR1, 79% sequence 
identity,[8] this site is very likely to influence the kinase activity of 
SPAK too.  
Despite the compelling in vivo evidence of WNK-SPAK/OSR1 
signaling inhibition yielding lowering in blood pressure,[6] there are 
currently no inhibitors of this signaling pathway in clinical 
development. However, numerous small molecules have been 
reported as potent inhibitors of WNK-SPAK/OSR1 signaling. 
These could be divided into two main groups; those which bind 
WNK kinases and the others which bind SPAK and OSR1. To 
date, only two compounds, WNK463[12] and compound 2[13], have 
been reported as WNK kinases inhibitors (structures not shown). 
However, few compounds that inhibit SPAK and OSR1 kinases 
directly without interfering with the kinase activity of WNKs have 
been described (Figure 3a).[14] 
Encouraged by our observation of the secondary pocket playing 
a role in regulating OSR1 kinase activity, we subsequently 
conducted in silico docking of known WNK-signaling inhibitors 
that bind SPAK and OSR1 into the crystal structure of the human 
OSR1 CCT domain. For this we used AutoDock[15] and docked 
STOCK1S-50699,[14b] STOCK2S-26016,[14b] STOCK1S-14279[14a] 
and Closantel[14a] (Figure 3a), which are all WNK-SPAK/OSR1 
signaling inhibitors, unbiasedly into the crystal structure of the 
reported OSR1 CCT domain. All of the docking possibilities 
placed Closantel and STOCK1S-50699 as well as the other 
reported small molecule WNK-signaling inhibitors in the 
secondary pocket (Figure 3b and supplementary Figures S1-3). 
Notably, a similar exercise using the RFQV tetrapeptide, which is 
known to bind the primary pocket[8] resulted in the docking of this 
tetrapeptide only in the primary pocket as expected (Figure 3b 
and supplementary Figures S4).  
Subsequently, we focused our efforts into studying Closantel and 
STOCK1S-50699. Since OSR1 T185E exhibits superior in vitro 
kinase activity to SPAK T233E,[16] we focused our work on OSR1 
T185E. In vitro kinase assays confirmed the ability of STOCK1S-
50699 and Closantel to inhibit OSR1 T185E in vitro, IC50 = 40.26 
μM and 8.65 μM and respectively (Figure 3c and 3e). The in vitro 
inhibition potency of STOCK1S-50699 (IC50 = 40.26 μM) is 
comparable to that reported[14b] in the initial discovery of 
STOCK1S-50699 (IC50 = 30-37 μM) though different kinase 
assays were used. The inability of Closantel and STOCK1S-
50699 to inhibit the constitutively active truncated version of 
OSR1 T185E 1-342 (Figure 3d, 3f and supplementary Tables S1-
2), which lacks the CCT domain and the secondary pocket, 
indicated that these inhibitors produce their action by binding to 
the CCT domain. Critically, these compounds were found to inhibit 
OSR1 T185E in vitro in an ATP-independent manner in 
Figure 2. Secondary pocket on OSR1 CCT domain affects its kinase activity. a) 
Single mutations in OSR1 T185E secondary pocket cause reduction in its 
kinase activity in vitro. *p <0.05 and **p <0.01. b) Fluorescence polarization 
analysis of the binding of OSR1 CCT wild-type (WT), primary pocket single point 
mutation (L473A), secondary pocket single point mutations (L440A and V507A) 
to an 18-mer RFQV peptide derived from WNK4. Data shown are the average 
signals with SD (n = 3). 
 
Lu
m
in
es
ce
nc
e 
(R
LU
)
 
TE
TE
/V
50
7A
TE
/S
44
3A
TE
/L
44
0A
GST-OSR1
a)
m
P
OSR1 CCT / µM
b)
WT (Kd = 2.11)
L473A (Kd = 13.17)
L440A (Kd = 2.83)
V507A (Kd = 1.75)
         
3 
 
agreement with previous observations (supplementary Figure 
S5).[14] These results explain the mechanism by which Closantel 
inhibits OSR1 T185E as it was first reported as a non-ATP 
competitive inhibitor of SPAK and OSR1, but the binding site was 
unknown.[14a] As for STOCK1S-50699, our data showed that it 
inhibits constitutively active OSR1 T185E in vitro in assay 
conditions that lack the upstream kinase WNK4. This was 
surprising since STOCK1S-50699 was discovered as in inhibitor 
of SPAK and OSR1 binding to WNK kinases.[14b] This suggests 
that STOCK1S-50699 may have a dual mechanism of action that 
involves the inhibition of active OSR1 T185E by binding to the 
secondary pocket of the C-terminal domain as well as preventing 
its binding to upstream kinases. Critically, this dual mechanism of 
action may explain the higher potency of STOCK1S-50699 in cells, 
where it completely inhibits the phosphorylation of the ion co-
transporters at a concentration nearly 3-fold lower than its in vitro 
IC50.[5a, 14b]  
To further test our finding of the secondary pocket of the CCT 
domain playing a role in regulating the kinase activity of OSR1, 
we next performed in silico screening of a 1,200 compounds FDA-
approved compounds aimed at identifying novel small molecules 
that bind the secondary pocket of OSR1 CCT domain. Among the 
top hits identified was Rafoxanide (Figure 4a), a potent anti-
parasitic agent[17] that is used to control infestations in animals. 
This compound stood out because of its structurally similarity to 
Closantel as they both share a 2-hydroxy-N-phenylbenzamide 
core. In vitro kinase assays using Rafoxanide showed it to be a 
low micromolar inhibitor of OSR1 T185E in vitro, IC50 = 8.18 μM 
(Figure 4b). Akin to Closantel and STOCK-1S-50699, 
Rafoxanide’s in vitro inhibition of OSR1 T185E was a result of 
binding to the CCT domain since it did not show any significant 
inhibition of active OSR1 T185E 1-342, which lacks the C-terminal 
domain (Figure 4c, supplementary Figure S6 and Table S3). 
Additionally, ATP-competition assay showed that Rafoxanide is 
not an ATP-competitive inhibitor of full length active OSR1 T185E 
(Figure 4d and supplementary Figure S7).  
Encouraged by Rafoxanide’s ability to inhibit OSR1 T185E in vitro, 
we explored its ability to inhibit SPAK T233E in vitro. In order to 
improve SPAK T233E’s in vitro activity, we run an in vitro kinase 
in the presence of the scaffolding protein MO25, which is known 
to enhance the in vitro activity of SPAK T233E by 80-fold.[16] The 
results indicated that Rofoxanide was also a low micromolar 
inhibitor of SPAK T233E in vitro (IC50 = 13.03 μM) (supplementary 
Figure S8). Notably, Rafoxanide was able to inhibit OSR1 T185E 
in vitro in the presence of MO25 with a similar potency (IC50 = 
13.91 μM) (supplementary Figure S8).     
Next, we studied Rafoxanide’s ability to inhibit SPAK and OSR1 
in cells. As shown in Figure 4e, treatment of HEK293 cells with 
hypotonic buffer[18] led to a significant increase in the 
phosphorylation of endogenous NKCC1 at residues T203, T207 
and T212, which are SPAK and OSR1 phosphorylation sites. 
Additionally, SPAK phosphorylation at S373 also increased 
following hypotonic treatment indicating the activation of WNK 
kinases. The addition of 10 μM STOCK1S-50699 inhibited WNK-
SPAK/OSR1 signaling as judged by lack of NKCC1 and SPAK 
S373 phosphorylation in agreement with previous reports.[5a] 
Interestingly, titration of Rafoxanide (1-50 μM) resulted in the 
inhibition of NKCC1 phosphorylation at residues T203, T207 and 
T212 indicating the inhibition of SPAK and OSR1 kinases similar 
to that observed with Closantel (Figure 4f). Total inhibition of 
these phosphorylation sites was observed at concentrations ≥ 20 
μM. Notably, SPAK phosphorylation at S373 was not inhibited by 
Rafoxanide and Closantel, unlike with STOCK1S-50699, 
confirming the ability of these compounds to inhibit SPAK and 
OSR1 but not its ability to interact with WNK kinases, which 
phosphorylate SPAK S373.  
In order to further establish that Rafoxanide binding to SPAK and 
OSR1 CCT domains does not take place in the primary pocket, 
we employed a biotin-streptavidin pulldown assay. For this, a 
biotinylated 18-mer RFQV peptide derived from human WNK4 
was used to pulldown endogenous SPAK from HEK293 cell 
lysates.[8] As a negative control, we used the 18-mer AFQV 
peptide, which is known not to bind the primary pocket of SPAK 
Figure 3. Known WNK-SPAK/OSR1 signaling inhibitors bind to OSR1 CCT domain secondary pocket. a) Chemical structures of the WNK-SPAK/OSR1 signaling 
inhibitors used in the in silico docking studies. b) AutoDock results of the four WNK-SPAK/OSR1 signaling inhibitors showing exclusive binding to the secondary 
pocket of OSR1 CCT domain. The tetrapeptide RFQV (green sticks) binds to the primary pocket of OSR1 CCT domain. ADP-Glo™ in vitro kinase assay of 
STOCK1S-50699 c) and Closantel e) showing inhibition of OSR1 T185E. ADP-Glo™ in vitro kinase assay of STOCK1S-50699 d) and Closantel f) showing that 
they do not inhibit truncated OSR1 T185E 1-342, which lacks the C-terminal domain. Data shown in c), d), e) and f) are the average signals with SD (n = 3). The 
dotted yellow lines in d) and f) indicate 50% of the maximum kinase activity. 
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and OSR1.[8] The pulldown was performed on cell lysates that 
either had been incubated with SPAK and OSR1 inhibitors, 
namely STOCK1S-50699, Closantel and Rafoxanide at the 
concentrations shown or left untreated (Figure 5a). The results 
showed that the 18-mer RFQV peptide was able to pull down 
endogenous SPAK while its mutant 18-mer AFQV peptide did not 
as expected.[8] Interestingly, Closantel and Rafoxanide did not 
compete with the 18-mer RFQV peptide, which binds to the 
primary pocket, even at high concentration (up to the 300 μM 
used) (Figure 5a). STOCK1S-50699 also failed to efficiently 
compete with the 18-mer RFQV peptide binding to SPAK except 
at high concentrations, 300 μM. Additionally, we carried out an FP 
assay for measuring the binding affinity of the 18-mer RFQV 
peptide derived from WNK4 to OSR1 CCT wild-type in presence 
of three different concentrations of Rafoxanide (1, 10 and 100 μM). 
The results showed that Rafoxanide was not able to compete with 
the RFQV peptide for binding to the primary pocket of OSR1 CCT 
wild-type even at 100 μM (Figure 5b). Collectively, the data shown 
in Figure 5 suggest that Rafoxanide and Closantel do not affect 
the 18-mer RFQV binding to OSR1 CCT domain primary pocket.   
In conclusion, the highly conserved CCT domain secondary 
pocket of SPAK and OSR1 kinases plays an important role in 
regulating their kinase activity. This small pocket could be 
targeted by small molecules such as Closantel and Rafoxanide 
resulting in the inhibition of SPAK and OSR1 kinase activity in 
vitro. This finding will facilitate the rationale design of allosteric 
SPAK and OSR1 kinase inhibitors that could serve as powerful 
tools in the decoding of WNK-SPAK/OSR1 signaling. Importantly, 
allosteric SPAK and OSR1 kinase inhibitors may eventually be 
useful agents in treating hypertension and other diseases with 
sodium, potassium and chloride (electrolyte) imbalances. 
Experimental Section 
Reagents 
Figure 4. Rafoxanide is a novel allosteric inhibitor of SPAK/OSR1 in vitro and in cells. a) Chemical structure of Rafoxanide. b) Rafoxanide inhibits full length OSR1 
T185E in vitro. The peptide CATCHtide was used as a substrate in the in vitro kinase assay. c) Rafoxanide does not inhibit the active truncated OSR1 T185E 1-
342 in vitro. d) Rafoxanide inhibits OSR1 T185E in an ATP-independent manner. NKCC1 (1-174) was used as a substrate in the in vitro kinase assay. e) Rafoxanide 
and f) Closantel inhibit endogenous SPAK and OSR1 kinases in HEK293 cells. HEK293 cells were first treated with Rafoxanide (e) or Closantel (f) at the indicated 
concentrations or STOCK1S5 0699 (10 μM) for 30 min and then either left untreated or treated with hypotonic buffer for 30 min to activate WNK-SPAK/OSR1 signal-
ling. The cells were then harvested, and the lysates were probed for phospho-NKCC1 T203, T207 and T212, total NKCC1, phospho-SPAKS373, total SPAK and 
GAPDH as a loading control. Data shown in b), c) and d) are the average signals with SD (n = 3). Data shown in e) and f) are representatives of three independent 
repeats. The dotted yellow line in c) indicates 50% of the maximum kinase activity. 
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Figure 5. Rafoxanide and Closantel do not compete with the 18-mer RFQV 
peptide for binding to the primary pocket. a) Biotinylated 18-mer RFQV peptide 
was used to pull-down endogenous SPAK from HEK293 cells in the absence 
or presence of the inhibitors at the indicated concentrations. The biotinylated 
18-mer AFQV peptide was used as a negative control. The data shown is 
representative of three independent repeats. b) Fluorescence polarization 
analysis of the binding of OSR1 CCT wild-type (WT) to the 18-mer RFQV 
peptide derived from WNK4 in the absence (DMSO) or presence of Rafoxanide 
at the indicated concentrations. Data shown are the average signals with SD 
(n = 3). 
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Rafoxanide, Closantel, tissue-culture reagents and protein expression 
materials were purchased from Sigma Aldrich. STOCK1S-50699 was 
purchased from Vitas-M Laboratory, Ltd while glutathione–sepharose 
beads were purchased from GE Healthcare. Peptides were purchased 
from GLS Peptide Synthesis (China). ADP-Glo™ Kinase Assay kit was 
purchased from Promega. Lumio Green (FlAsH-EDT2) was purchased 
from Carbosynth.  
 
Buffers 
Cells Lysis Buffer: 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 50 
mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM sodium 
orthovanadate, 1% (w/v) Nonidet P40, 0.27 M sucrose, 0.1% (v/v) 2-
mercaptoethanol, 0.1 mM PMSF, 1 mM benzamidine. Bacterial lysis buffer: 
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 0.27 M 
sucrose, 0.1 mM PMSF, 1 mM benzamidine, 0.5 mg/ml lysosome, 0.3 
mg/ml DNase and 0.01% (v/v) 2-mercaptoethanol. Buffer A: 50 mM Tris-
HCl (pH 7.5), 0.1 mM EGTA and 0.1% (v/v) 2-mercaptoethanol. Normal 
buffer: bacterial lysis buffer without lysozome and DNase. High salt buffer: 
normal buffer with 500 mM NaCl. Protein elution buffer: buffer A and 20 
mM reduced glutathione (pH 8). TBS-T buffer: 50 mM Tris-HCl (pH 7.5), 
150 mM NaCl and 0.2% (v/v) Tween-20. Running buffer: 34.6 mM SDS, 25 
mM Tris-base and 1.92 M glycine. Transfer buffer: 48 mM Tris-base, 39 mM 
glycine containing 20% (v/v) Methanol. Hypotonic low-chloride buffer: 67.5 
mM sodium gluconate, 2.5 mM potassium gluconate, 0.25 mM CaCl2, 0.25 
mM MgCl2, 0.5 mM Na2HPO4, 0.5 mM Na2SO4 and 7.5 mM HEPES. SDS 
sample buffer (4X): 40 % glycerol, 240 mM Tris-HCl (pH 6.8), 8% SDS, 
0.04% bromophenol blue and 5% 2-mercaptoethanol. Blocking buffer: 
10% (w/v) dried skimmed milk in TBST. Dialysis buffer: 50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl and 2 mM dithiothreitol (DTT). 
 
Antibodies 
SPAK phospho-Ser373 antibody (residues 367–379) of human SPAK 
phosphorylated at Ser373 [S670B], NKCC1 total-antibody (residues 1-
260) of shark NKCC1 [DU 6146], NKCC1 phospho-Thr 203+Thr 207+Thr 
212 antibody (residues 198-217) of human NKCC1 phosphorylated at Thr 
203 +Thr 207  +Thr 212 [S763B] and SPAK total-antibody (full length) of 
human SPAK [S551D] were purchased from Division of Signal 
Transduction Therapy Unit (University of Dundee). SPAK total-antibody 
[2281S] were from Cell Signaling Technology, GAPDH antibody [MA5-
15738], Horseradish peroxidase (HRP)-labelled GST-total antibody [MA4-
004-HRP], anti-sheep [31480] and anti-rabbit [31460] secondary 
antibodies conjugated to HRP were purchased from Thermo Scientific. 
 
Plasmids, protein expression and purification 
DNA clones were purchased from the Division of Signal Transduction 
Therapy (University of Dundee);  pGEX-6P-1-OSR1 (433-end) [DU10096], 
pGEX-6P-1-OSR1 (433-end) L440A [DU 10332], pGEX-6P-1-OSR1 (433-
end) V507A [DU 10331], pGEX-6P-1-OSR1 (433-end) S443A [DU 10330] 
and pGEX-6P-1-OSR1 (433 – end) L473A [DU 10321]. The proteins were 
expressed in E. Coli and purified as described elsewhere[16]. 
 
Cell culture and transfection  
Human embryonic kidney 293 (HEK-293) cells were cultured on either 6-
well plates or 10-cm dishes in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% (v/v) fetal bovine serum, 2 mM L-
glutamine, 100 units/ml penicillin and 0.1 mg/ml streptomycin at 37 °C in a 
humidified 5% CO2 incubator. For transfection, OSR1 T185E was 
transfected into cells using 20 μl of 1 mg/ml polyethylenimine 
(Polysciences) and 3 μg of plasmid DNA [19]. After 36 h transfection, cells 
were lysed in 0.4 ml of ice-cold lysis buffer. The lysates were clarified by 
centrifugation at 4 °C for 15 min at 26,000 g and the supernatants were 
stored at −80 °C. For inhibition studies, cells were incubated with each 
compound at indicated concentrations for 40 minutes then stimulated with 
low chloride hypotonic buffer to activate WNK signaling for 30 minutes. 
Then cells were lysed with 0.15 mL ice cold cells lysis buffer and 
centrifuged at 12000 g at 4 ºC for 10 minutes to collect the protein. The 
final DMSO concentration was < 0.1%. 
 
Immunoblotting  
Twenty μg of cell lysates, 0.2–1 μg of purified proteins or 
immunoprecipitates in SDS sample buffer were subjected to 
electrophoresis on a polyacrylamide gel and transferred to nitrocellulose 
membranes. The membranes were incubated for 1 h with TBS-T 
containing either 10% (w/v) skimmed milk powder (for antibodies raised in 
sheep) or 5% (w/v) BSA (for all other antibodies). The membranes were 
then immunoblotted in the same buffer for 1 h at room temperature with 
the indicated primary antibodies. Sheep antibodies were used at a 
concentration of 0.5–1 μg/ml, whereas commercial antibodies were diluted 
to 1000-fold. The incubation with phosphospecific sheep antibodies was 
performed with the addition of 10 μg/ml of the dephosphopeptide antigen 
used to raise the antibody. The blots were then washed six times with 
TTBS and incubated with secondary HRP-conjugated antibodies in 5% 
skimmed milk. After repeating the washing steps, the signal was detected 
with the enhanced chemiluminescence reagent. Immunoblots were 
developed using a film automatic processor (SRX-101; Konica Minolta 
Medical), and films were scanned with a 300-dp1 resolution on a scanner 
(PowerLook 1000; UMAX). 
 
ADP-Glo™ in vitro kinase assay 
350 μg of HEK293 lysates overexpressing GST-tagged full-length OSR1 
T185E, wild-type or with secondary pocket mutations was incubated with 
10 μL of sepharose-beads at 4 ºC.  After 1 hour, the suspension was 
centrifuged at 3000 g at 4 ºC for 2 minutes. The beads then washed two 
times with cold lysis buffer containing 0.5 M NaCl and two times with buffer 
A. 10 µl aliquot of the kinase loaded sepharose beads was used in an in 
vitro kinase assay employing 0.25 mM CATCHtide (RRHYYYDTHTNTYY 
LRTFGHN TRR)[7]. Kinase reactions were performed for 40 minutes at 
30 °C with gentle agitation in 25 μl reaction buffer consisting of 50 mM Tris-
HCl, 10 mM MgCl2, 0.1% (v/v) 2-mercaptoethanol, 0.1 mM ATP.  The 
mixture was then transferred to a 96 well plate and developed using the 
Promega’s ADP-Glo™ kit instructions[10] and the plate was subsequently 
read on a BMG FLUOstar Omega plate reader. For testing kinase assays 
that determined the IC50 values of the inhibitors, the kinase assay was 
performed in 384 well plates by incubating increasing concentration of 
inhibitors with GST-OSR1 T185E purified from E.Coli at 5 µL total reaction 
volume. The kinase activity was assayed using ADP-Glo™ kinase assay 
according to the manufacturer's protocol[10]. The plate was subsequently 
read on a BMG FLUOstar Omega plate reader. The final DMSO 
concentration was < 4%. Each sample was run in triplicate and the 
experiment was run three independent times. Data presented in figures is 
the average signal with SD (n = 3).  
 
Fluorescence Polarization Assay (FP) 
The RFQV peptide (CCPGCCGGSEEGKPQLVGRFQVTSSK) powder 
was initially resuspended in 50 mM NH4HCO3 (pH 8). Subsequently, it was 
labeled with FlAsH-EDT2 fluorophore that binds covalently to the CCPGCC 
N-terminal motif on the RFQV peptide. The labeling step was achieved by 
incubating 10 μM of peptide with 30 μM of FlAsH-EDT2 in 500 μl dialysis 
buffer in the dark at 4 °C for 2 h. The peptides were then dialyzed for 4 h 
into dialysis buffer using a Mini Dialysis kit with 1 kD cut-off (GE 
Healthcare) and then for another 12 h with a fresh dialysis buffer. The 
optimum FlAsH-EDT2 concentration that exhibited about ten times more 
fluorescence intensity signal compared to background controls was 10 nM. 
For the fluorescence polarization studies, 10 nM of FlAsH-EDT2 labelled 
peptide was mixed with proteins at various concentrations (0.005-5 μM) in 
dialysis buffer in a final volume of 30 μL. Each assay was performed in 
triplicate with at least twelve data points per curve and repeated three 
independent times. A BMG PheraStar plate reader was used to measure 
the fluorescence polarization, with an excitation and emission wavelengths 
of 485 nm and 538 nm, respectively.[11] Data presented in figures is the 
average signal with SD (n = 3). 
 
AutoDock docking 
Autodock Vina 1.1.2[20] was used to dock the current available WNK 
signaling inhibitors against the crystal structure of OSR1 CCT (PDB ID: 
2V3S). AutoDock tool 1.5.6[21] was used for preparation of pdbqt files of 
proteins and ligands. The unbiased docking approach was initially 
optimized in term of docking exhaustiveness and subsequently validated 
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by re-docking WNK4-RFQV into OSR1 CCT (PDB ID: 2V3S) and PP1 into 
Hck ATP site (PDB ID:1QCF). The same approach was used to perform 
structure-based virtual screening (SBVS) of 1200 FDA-approved 
compounds using PyRx virtual screening tool. The docking results were 
visualized and analyzed using Discovery Studio 4.5 (Accelrys, San Diego, 
CA) and PyMOL Molecular Graphics System 1.3. 
 
Biotin-streptavidin pulldown assay 
250 μg of pre-cleared HEK-293 total cells lysates were incubated with 
inhibitors at the indicated concentrations for 2 h at 4 ºC. 3 μg of biotinylated 
18-mer RFQV-containing peptide derived from WNK4 (biotin-
SEEGKPQLVGRFQVTSSK) or the 18-mer AFQV-containing peptide 
(biotin-SEEGKPQLVGAFQVTSSK) were added and incubated under the 
same condition for a further 15 minutes at 4 ºC. Then, to each sample 20 
μl of streptavidin beads equilibrated in cells lysis buffer (pre-washed 3X 
with phosphate-buffered saline) was added and incubated for 15 minutes 
at 4 ºC. After the incubation, the beads were washed two times with cell 
lysis buffer and twice with Buffer A, respectively. Then, they were boiled 
with 1XSDS sample buffer and subjected to SDS-PAGE. The data shown 
is a representative of three independent repeats. 
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Entry for the Table of Contents 
 
 
SPAK and OSR1 kinases regulate electrolyte balance in vivo. Herein, we identify a small pocket on their C-terminal domains that has 
a role in regulating their kinase activity. Using in silico screening, we discovered Rafoxanide as a novel allosteric inhibitor of these two 
protein kinases. Together, these findings will facilitate the discovery of allosteric SPAK and OSR1 inhibitors with potential 
antihypertensive effects.  
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Supporting Information 
 
 
 
Supplementary figure S1. Docking of STOCK1S-50699 into OSR1 CCT domain using AutoDock 
Vina®. 
 
 
 
Supplementary figure S2. Docking of Closantel into OSR1 CCT domain using AutoDock Vina®. 
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Supplementary figure S3. Docking of STOCK1S-50699 (green), Closantel (pink) and Rafoxanide 
(yellow) into OSR1 CCT domain using AutoDock Vina®. 
 
 
 
Supplementary figure S4. Docking of RFQV tetrapeptide into OSR1 CCT domain using AutoDock 
Vina®. 
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Supplementary figure S5. STOCK1S-50699 inhibits OSR1 T185E in vitro in an ATP-independent 
manner. 
 
 
 
 
 
 
Supplementary figure S6. Docking of Rafoxanide in OSR1 CCT using AutoDock Vina®. OSR1 R441, 
L473 and S505 formed key hydrogen interactions with Rafoxanide. 
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Supplementary figure S7. Rafoxanide inhibits OSR1 T185E in vitro in an ATP-independent manner. 
The peptide, CATCHtide, was used as a substrate in this assay. 
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Supplementary figure S8. Rafoxanide inhibits both OSR1 TE (a) and SPAK TE (b) in vitro in the 
presence of MO25. The assay was performed in 384-well plate by incubating 1 µl of Rafoxanide at 
different concentrations with 0.2 µM GST-OSR1 T185E or 0.5 µM SPAK T233E in presence of 5 molar 
excess of MO25. The reaction was conducted in a 5 µl total reaction volume containing 50 mM Tris/HCl, 
10 mM MgCl2, 0.1% (v/v) 2-mercaptoethanol, 0.1 mM ATP employing 0.3 mM CATCHtide 
(RRHYYYDTHTNTYYLRTFGHNTRR) as substrate in buffer A at 30 °C for 30 min with gentle agitation. 
The kinase activity was assayed using ADP-GloÔ kinase assay according to the manufacturer's protocol. 
The plate was subsequently read on a BMG FLUOstar Omega plate reader. Data shown is the average 
of signals with SD (n = 3). 
 
 
 
 
a 
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Concentration 
(µM) Luminescence (RLU) ±SE 
DMSO 5971.17 982.65 
0.10 3933.67 134.72 
0.20 3774.67 330.68 
0.39 4116.67 153.50 
0.78 4097.17 72.26 
1.56 4384.67 476.02 
3.125 4652.67 596.04 
6.25 4168.67 673.61 
12.5 5217.17 261.69 
25 5147.67 360.07 
100 4585.17 656.87 
Table S1. In vitro ADP-Glo™ kinase assay raw data of OSR1 T185E 1-342 in presence of the 
indicated concentrations of STOCK1S-50699. 
 
 
Concentration 
(µM) Luminescence (RLU) ±SE 
DMSO 19822.25 729.01 
0.25 15989.50 397.80 
0.5 15400.33 408.96 
1 16605.00 263.72 
3 14339.00 1354.28 
5 17762.33 230.34 
10 20208.33 885.13 
15 16607.33 430.78 
20 17118.33 74.96 
Table S2. In vitro ADP-Glo™ kinase assay raw data of OSR1 T185E 1-342 in presence of the 
indicated concentrations of Closantel. 
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Concentration 
(µM) Luminescence (RLU) ±SE 
DMSO 19845.00 989.36 
0.1 16143.00 459.92 
1 17974.50 1664.57 
3 16464.50 651.32 
5 17871.50 343.93 
10 17022.25 369.81 
15 18573.75 1342.70 
20 20690.67 2177.09 
30 17572.25 622.16 
50 15482.00 742.88 
80 16050.00 712.93 
100 15582.75 1104.13 
Table S3. In vitro ADP-Glo™ kinase assay raw data of OSR1 T185E 1-342 in presence of the 
indicated concentrations of Closantel. 
 
